Use of omalizumab in women Mexican patients diagnosed with moderate to severe non-atopic asthma: an observational real-life study in a university hospital

Abstract

ntroduction: While up to 50% of patients with moderate to severe asthma have no evidence of allergy, IgE has been linked to asthma regardless of atopic status. It has already been described that omalizumab, an anti-IgE monoclonal antibody, significantly benefits a subset of patients with non-atopic asthma. Methods: 20 Adult patients who, despite daily treatment with or without maintenance oral corticosteroids, had uncontrolled moderate to severe non-atopic asthma, were assigned to receive omalizumab at doses of IgE levels. The primary endpoint was the change in the clinical and functional parameters of the patients by means of asthma control examination. Results: After 52 weeks of administration of Omalizumab they showed a moderate increase in FEV1, clinical and functional parameters. The symptomatic improvement of the patients was mainly due to an ACT increase of 10 to 20 points. Good tolerance to the drug was also observed, without any serious adverse effects and improvement in the quality of life of the patients. Conclusions: Omalizumab down regulates the expression of FcεRI in patients with moderate to severe non-atopic asthma at the local level, decreasing the multifunctional and immunomodulatory expression of immunoglobulin E (IgE). Omalizumab has a therapeutic role in moderate to severe non-atopic asthma. Our results support the clinical efficacy of omalizumab in Mexican non-atopic asthmatic patients equal to other countries.